Translational spotlight on Alzheimer's targets

As clinical data continue to roll in for leading amyloid-targeting agents, preclinical researchers are exploring alternative ways of addressing the disease, including clusters of targets with tauopathy and microglia-based mechanisms, and an independently discovered pair of ATPase targets.

Targets and technologies captured in BioCentury’s Distillery, a curated database of translational academic research from over 25 journals, represent a cross-section of innovations with disease-modifying effects in preclinical models. Of the 14 Alzheimer’s targets proposed by papers in the Distillery since Jan. 2021, nine also had patient biomarker data supporting their role in the disease...